Related Experiment Video
Updated: Jun 2, 2026
12:57
Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
Published on: January 8, 2015
Genetics of prion disease
Sarah Lloyd1, Simon Mead, John Collinge
1MRC Prion Unit and Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, WC1N 3BG, UK.
Topics in Current Chemistry
|April 30, 2011
Summary
Prion diseases, a group of neurodegenerative disorders, lack effective treatments. Research is identifying genetic modifiers like RARB, HECTD2, and SPRN that influence disease susceptibility and progression.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Prion diseases, or transmissible spongiform encephalopathies (TSEs), are fatal neurodegenerative conditions affecting humans and animals.
- The abnormal prion protein (PrPSc) is the key infectious agent, accumulating in affected brains.
- Both inherited mutations in the prion protein gene (PRNP) and genetic variations influence disease susceptibility and presentation.
Purpose of the Study:
- To investigate the role of non-PRNP genetic modifiers in prion disease.
- To understand the biological mechanisms underlying prion disease susceptibility and incubation time.
Main Methods:
- Human genome-wide association studies (GWAS).
- Mouse mapping studies.
- Differential gene expression analysis.
Main Results:
- Identification of novel genetic modifiers, including RARB (retinoic acid receptor beta), HECTD2 (E3 ubiquitin ligase), and SPRN (Shadoo).
- These genes contribute to variations in prion disease susceptibility and incubation periods.
Conclusions:
- Non-PRNP genes play a significant role in modulating prion disease.
- Further research into these genetic modifiers may reveal new therapeutic targets and insights into neurodegeneration.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:43Incomplete Dominance
Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
01:29Subviral Agents
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...